• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Venus Concept Inc. (Amendment)

    2/29/24 8:14:53 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email
    SC 13D/A 1 d10993316_13d-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

     

    Venus Concept Inc.
    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

     

     

    92332W204
    (CUSIP Number)

     

    Masters Capital Management, LLC

    3060 Peachtree Road, NW, Suite 1425

    Atlanta, Georgia 30305

    Telephone- (404) 364-2021

    (Name, Address and Telephone Number of Person Authorized to Receive

    Notices and Communications)

     

    February 27, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [  ].
     
    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.
       
    *   The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     


    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    CUSIP No. 92332W204    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Masters Special Situations, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [x]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF, WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Georgia  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      539,9451  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARES DISPOSITIVE POWER   [_]
         
      539,9451  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
     

     

    539,9451

     
         

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES*  
         

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      7.44%  

     

    14. TYPE OF REPORTING PERSON  
         
      IA, OO  
         

     


    1 Comprised of (i) 306,612 shares of Common Stock (as defined herein) and (ii) 233,333 shares of Common Stock issuable upon conversion of 350,000 shares of voting convertible preferred stock, par value $0.0001 per share (“Voting Preferred Stock”).

     
     

     

    CUSIP No. 92332W204    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Masters Capital Management, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [x]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF, WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Georgia  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      1,000,0002  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARES DISPOSITIVE POWER   [_]
         
      1,000,0002  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
         
      1,000,0002  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES*  
         

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      13.78%  

     

    14. TYPE OF REPORTING PERSON  
         
      IA, OO  

     

     

     


    2 Comprised of (i) 333,333 shares of Common Stock (as defined herein) and (ii) 666,667 shares of Common Stock issuable upon conversion of 1,000,000 shares of Voting Preferred Stock.

     
     

     

    CUSIP No. 92332W204    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Michael Masters  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [x]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF, WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      1,539,9453  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

     

    10. SHARES DISPOSITIVE POWER   [_]
         
      1,539,9453  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
     

     

    1,539,9453

     

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES*  
         

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      21.23%  

     

    14. TYPE OF REPORTING PERSON  
         
      IN, HC  
         

     

     


    3 Comprised of (i) 639,945 shares of Common Stock (as defined herein) and (ii) 900,000 shares of Common Stock issuable upon conversion of 1,350,000 shares of Voting Preferred Stock.

     
     

     

     

    CUSIP No. 92332W204    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Marlin Fund, Limited Partnership  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [x]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF, WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Georgia  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      502,9804  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARES DISPOSITIVE POWER   [_]
         
      502,9804  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
     

     

    502,9804

     

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES*  
         

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      6.93%  

     

    14. TYPE OF REPORTING PERSON  
         
      IA, OO  
         

     


    4 Comprised of (i) 172,313 shares of Common Stock (as defined herein) and (ii) 330,667 shares of Common Stock issuable upon conversion of 496,000 shares of Voting Preferred Stock.

     
     

     

     

     


    CUSIP No.
    92332W204    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Marlin Fund II, Limited Partnership  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [x]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF, WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Georgia  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      390,9205  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

     

    10. SHARES DISPOSITIVE POWER   [_]
         
      390,9205  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
     

     

    390,9205

     

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES*  
         

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      5.39%  

     

    14. TYPE OF REPORTING PERSON  
         
      IA, OO  
         

     


    5 Comprised of (i) 128,253 shares of Common Stock (as defined herein) and (ii) 262,667 shares of Common Stock issuable upon conversion of 394,000 shares of Voting Preferred Stock.

     
     

     

     

     


    CUSIP No.
    92332W204    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      MSS VC SPV LP  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [x]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF, WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      539,9456  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARES DISPOSITIVE POWER   [_]
         
      539,9456  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
     

     

    539,9456

     

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES*  
         

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      7.44%  

     

    14. TYPE OF REPORTING PERSON  
         
      IA, OO  
         

     

     

     


    6 Comprised of (i) 306,612 shares of Common Stock (as defined herein) and (ii) 233,333 shares of Common Stock issuable upon conversion of 350,000 shares of Voting Preferred Stock.

     
     

     

    CUSIP No. 92332W204    
         

     

    Item 1. Security and Issuer.  
         
      Pursuant to Rule 13d-2 promulgated under the Act, this Schedule 13D/A (this “Amendment No.2”) amends the Schedule 13D/A filed on November 21, 2022 (the “Amendment No.1”) (the initial Schedule 13D filed on December 23, 2021, Amendment No. 1 and this Amendment No.2 are collectively referred to herein as the “Schedule 13D”). This Amendment No. 2 relates to the Common Stock, $0.0001 par value per share (“Common Stock”) of Venus Concept Inc., a corporation incorporated under the laws of the State of Delaware, U.S.A. with its principal executive offices located at 235 Yorkland Blvd., Suite 900, Toronto, Ontario M2J 4Y8 (the “Issuer”).  Except as otherwise provided herein, each Item of the Schedule 13D remains unchanged.  
         
         
    Item 2. Identity and Background.  
         
      Item 2 is hereby amended and supplemented as follows:  
         
      (a)-(c), (f)

    This Schedule 13D is being filed jointly by (i) Masters Special Situations, LLC, a Georgia limited liability company (“MSS”), (ii) Masters Capital Management, LLC, a Georgia limited liability company (“MCM”), (iii) Michael Masters, a United States citizen, (iv) Marlin Fund, Limited Partnership, a Georgia limited partnership (“MFLP”), (iv) Marlin Fund II, Limited Partnership, a Georgia limited partnership (“MFIILP”), and (v) MSS VC SPV LP, a Delaware limited partnership (“MSSVC”) (collectively, the “Reporting Persons”).

     

    The principal business address of the Reporting Persons is 3060 Peachtree Road, NW, Suite 1425, Atlanta, Georgia 30305.

     

    Michael Masters is the controlling founder of each of MSS and MCM, each an investment management firm that serves as the investment manager to certain private funds, including MFLP, MFIILP, Marlin Fund III Limited Partnership (“MFIIILP”), Marlin Master Fund Offshore II, LP (“MMFO”) and MSSVC.

     
           
      (d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).  
           
      (e) None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.  
           
         
         

     

     
     

     

         

     

     

    Item 3. Source and Amount of Funds or Other Consideration.  
         
     

    The funds for the purchase of the Common Stock beneficially owned by the Reporting Persons came from the working capital of the private funds managed by each of MSS and MCM (including MFLP, MFIILP and MSSVC).

     

    No borrowed funds were used to purchase the shares of Common Stock, other than any borrowed funds used for working capital purposes (including certain leverage arrangements) in the ordinary course of business.

     
         
         
    Item 4. Purpose of Transaction.  
         
     

    Item 4 is hereby supplemented by adding thereto the following:

     

    On February 27, 2024, the Issuer sold 817,748 shares of Common Stock to certain institutional investors pursuant to a prospectus supplement, filed with the Securities and Exchange Commission (the “Commission”) on February 27, 2024, and a prospectus, dated October 25, 2021, filed with the Commission as a part of the Issuer’s registration statement on Form S-3 (File No. 333-260267) (the “Public Offering”). In addition, on February 27, 2024, in a concurrent private placement, the Issuer also sold to the investors private placement warrants to purchase 817,748 shares of Common Stock (the “Private Placement,” and together with the Public Offering, the “Offerings”). The Reporting Persons did not participate in either the Public Offering or the Private Placement. This Amendment No. 2 is being filed solely to report a greater than 1% decrease in the percentage of shares of Common Stock beneficially owned by the Reporting Persons due to the increase of shares of Common Stock outstanding as a result of the Public Offering.

     

    On May 11, 2023, the Issuer effected a reverse stock split (the “Reverse Stock Split”) of the Issuer’s Common Stock at a ratio of 15:1. The share and per share amounts reported in this Schedule 13D give effect to the Reverse Stock Split for all periods presented herein, except as otherwise noted.

     

    Except as otherwise set forth herein, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D.

     

    The Reporting Persons reserve the right, at a later date, to effect one or more of such changes or transactions in the number of Shares they may be deemed to beneficially own.

     
     
     

     

         
    Item 5. Interest in Securities of the Issuer.  
         
      (a)-(c)

    As of the date of this Amendment No. 2 to Schedule 13D, (i) Michael Masters may be deemed to be the beneficial owner of 1,539,945 shares of Common Stock or 21.23% of the shares of Common Stock of the Issuer, (ii) MSS may be deemed to be the beneficial owner of 539,945 shares of Common Stock or 7.44% of the shares of Common Stock of the Issuer, (iii) MCM may be deemed to be the beneficial owner of 1,000,000 shares of Common Stock or 13.78% of the shares of Common Stock of the Issuer, (iv) MFLP may be deemed to be the beneficial owner of 502,980 shares of Common Stock or 6.93% of the shares of Common Stock of the Issuer, (v) MFIILP may be deemed to be the beneficial owner of 390,920 shares of Common Stock or 5.39% of the shares of Common Stock of the Issuer, and (vi) MSSVC may be deemed to be the beneficial owner of 539,945 shares of Common Stock or 7.44% of the shares of Common Stock of the Issuer, in each case based upon the 6,355,230 shares of Common Stock outstanding as of February 27, 2024 following the consummation of the Public Offering according to the Issuer (which excludes, for the avoidance of doubt, outstanding Voting Preferred Stock).

     

    Michael Masters has the sole power to vote or direct the vote of 0 shares of Common Stock and the shared power to vote or direct the vote of 1,539,945 shares of Common Stock.

     

    MSS has the sole power to vote or direct the vote of 0 shares of Common Stock and the shared power to vote or direct the vote of 539,945 shares of Common Stock.

     

    MCM has the sole power to vote or direct the vote of 0 shares of Common Stock and the shared power to vote or direct the vote of 1,000,000 shares of Common Stock.

     

    MFLP has the sole power to vote or direct the vote of 0 shares of Common Stock and the shared power to vote or direct the vote of 502,980 shares of Common Stock.

     

    MFIILP has the sole power to vote or direct the vote of 0 shares of Common Stock and the shared power to vote or direct the vote of 390,920 shares of Common Stock.

     

    MSSVC has the sole power to vote or direct the vote of 0 shares of Common Stock and the shared power to vote or direct the vote of 539,945 shares of Common Stock.

     

    Michael Masters has the sole power to dispose or direct the disposition of 0 shares of Common Stock and the shared power to dispose or direct the disposition of 1,539,945 shares of Common Stock.

     

    MSS has the sole power to dispose or direct the disposition of 0 shares of Common Stock and the shared power to dispose or direct the disposition of 539,945 shares of Common Stock.

     

    MCM has the sole power to dispose or direct the disposition of 0 shares of Common Stock and the shared power to dispose or direct the disposition of 1,000,000 shares of Common Stock.

     

    MFLP has the sole power to dispose or direct the disposition of 0 shares of Common Stock and the shared power to dispose or direct the disposition of 502,980 shares of Common Stock.

     

    MFIILP has the sole power to dispose or direct the disposition of 0 shares of Common Stock and the shared power to vote or direct the vote of 390,920 shares of Common Stock.

     

    MSSVC has the sole power to dispose or direct the disposition of 0 shares of Common Stock and the shared power to dispose or direct the disposition of 539,945 shares of Common Stock.

     

    There have been no transactions in the securities of the Issuer by the Reporting Persons during the last sixty days.

     

    The aforementioned shares of Common Stock were acquired for investment purposes. The Reporting Persons may acquire additional securities of the Issuer, dispose of all or some of these securities from time to time, in each case in open market or private transactions, block sales or purchases or otherwise, or may continue to hold the Common Stock.

     

    The Reporting Persons specifically disclaim beneficial ownership in the shares of Common Stock reported herein except to the extent of their pecuniary interest therein.

     
           
           
    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.  
         
      This Item is not applicable.  
         
    Item 7. Material to be Filed as Exhibits.  
         
      An agreement relating to the filing of a joint statement as required by Rule 13d-1(f) under the Securities Exchange Act of 1934 is filed herewith as Exhibit A.  

     

     

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 29, 2024
      (Date)

     

      Masters SPECIAL SITUATIONS, LLC
       
       
      By: /s/ Michael Masters
        Michael Masters, Authorized Signatory
         
         
      MASTERS CAPITAL MANAGEMENT, LLC
         
         
      By: /s/ Michael Masters
        Michael Masters, Managing Member
         
      MICHAEL MASTERS
         
        /s/ Michael Masters
         
         
      MARLIN FUND, LIMITED PARTNERSHIP
         
      By: /s/ Michael Masters
        Michael Masters, Authorized Signatory
         
         
      MARLIN FUND II, LIMITED PARTNERSHIP
         
      By: /s/ Michael Masters
        Michael Masters, Authorized Signatory
         
         
      MSS VC SPV LP
         
      By: /s/ Michael Masters
        Michael Masters, Authorized Signatory
         

     

     

     

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

    Exhibit A

     

    AGREEMENT

     

    The undersigned agree that this Amendment No. 2 to Schedule 13D, dated February 29, 2024, relating to the Common Stock of Venus Concept Inc. shall be filed on behalf of the undersigned.

     

     

    February 29, 2024  
    (Date)  

     

    MASTERS SPECIAL SITUATIONS, LLC  
       
    By: /s/ Michael Masters  
      Michael Masters, Authorized Signatory  
         
         
    MASTERS CAPITAL MANAGEMENT, LLC  
         
         
    By: /s/ Michael Masters  
      Masters, Managing Member  
         
    MICHAEL MASTERS  
         
      /s/ Michael Masters  
         
         
    MARLIN FUND, LIMITED PARTNERSHIP  
         
    By: /s/ Michael Masters  
      Michael Masters, Authorized Signatory  
         
         
    MARLIN FUND II, LIMITED PARTNERSHIP  
         
    By: /s/ Michael Masters  
      Michael Masters, Authorized Signatory  
         
         
    MSS VC SPV LP  
         
    By: /s/ Michael Masters  
      Michael Masters, Authorized Signatory  
         

     

     

     

     

     

    Get the next $VERO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 869,440 shares of common stock at an exercise price of $2.65 per share that will be immediately exercisable upon issuance and will expire eighteen months following the effective date of the regist

      6/6/25 11:35:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today it has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd ("Meta Healthcare Group") in an all-cash transaction valued at $20 million, subject to a customary working capital adjustment. The net proceeds from the transaction, once completed, will enhance the Company's balance sheet and financial condition and provide valuable capital to fund strategic growth initiatives. "We are pleased to announce one outcome of our evaluation of strategic alternatives to maximize shareholder value," sai

      6/6/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces First Quarter 2025 Financial Results

      TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2025. Summary of Financial Results & Recent Progress: Total revenue for the first quarter of $13.6 million, down 22% year-over-year, reflecting continued difficult market conditions. First quarter operating expenses declined 6% year-over-yearFirst quarter GAAP net loss of $12.4 million, compared to $9.8 million last yearFirst quarter Adjusted EBITDA loss of $8.3 million, compared to $5.1 million last year On April 1, 2025, the Company exchanged $11.0 million of its sub

      5/15/25 7:00:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Madryn Asset Management, Lp

      4 - Venus Concept Inc. (0001409269) (Issuer)

      4/2/25 5:47:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Director Natale Anthony sold $13,194 worth of shares (42,768 units at $0.31) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      12/4/24 5:43:14 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Large owner Masters Michael Willingham sold $179,641 worth of shares (306,135 units at $0.59) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      10/2/24 7:54:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    SEC Filings

    See more
    • Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Venus Concept Inc. (0001409269) (Filer)

      6/6/25 5:07:51 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Venus Concept Inc. (0001409269) (Filer)

      6/2/25 4:28:55 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Venus Concept Inc.

      SD - Venus Concept Inc. (0001409269) (Filer)

      5/30/25 7:00:18 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/8/24 7:51:38 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/3/24 7:59:41 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

      SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

      9/30/24 9:53:26 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Leadership Updates

    Live Leadership Updates

    See more
    • Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

      TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

      10/12/23 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

      TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

      10/11/22 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Ross J. Portaro as President of Global Sales

      TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

      10/12/21 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Financials

    Live finance-specific insights

    See more
    • Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

      TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

      4/7/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

      TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2024 financial results will be released before the market opens on Monday, March 31, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on March 31, 2025 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13751985. A live webcast of the call will also be provided on the investor relations section of the

      3/3/25 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Third Quarter of Fiscal Year 2024 Financial Results on November 13, 2024

      TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, November 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13749236. A live webcast of the call will also be provided on the investor relations section of the Company's

      10/2/24 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care